AA
FPRX

ALPS Advisors’s Five Prime Therapeutics, Inc. FPRX Stock Holding History

ALPS Advisors’s Portfolio FPRX Stock Details FPRX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2019
Q2 		– Sell
-85,663
Closed -$1.15M – 907
2019
Q1 		$1.15M Buy
85,663
+3,707
+5% +$42.3K 0.01% 296
2018
Q4 		$762K Buy
81,956
+18,995
+30% +$226K 0.01% 364
2018
Q3 		$876K Buy
62,961
+11,871
+23% +$177K 0.01% 438
2018
Q2 		$808K Buy
51,090
+5,474
+12% +$95.5K 0.01% 394
2018
Q1 		$784K Buy
45,616
+13,558
+42% +$264K 0.01% 364
2017
Q4 		$703K Buy
32,058
+3,728
+13% +$120K ﹤0.01% 327
2017
Q3 		$1.16M Buy
28,330
+2,364
+9% +$74.2K 0.01% 230
2017
Q2 		$782K Buy
25,966
+1,498
+6% +$46.8K 0.01% 271
2017
Q1 		$885K Sell
24,468
-11,617
-32% -$512K 0.01% 229
2016
Q4 		$1.81M Sell
36,085
-8,718
-19% -$458K 0.01% 183
2016
Q3 		$2.35M Sell
44,803
-7,191
-14% -$343K 0.02% 174
2016
Q2 		$2.15M Buy
51,994
+38,705
+291% +$1.68M 0.02% 166
2016
Q1 		$540K Buy
+13,289
New +$457K 0.01% 208

Other funds holding FPRX

BI
BVF Inc San Francisco, California $3.14B AUM 249.53% 1-Year Est. Return
Wellington Management Group
Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
Dimensional Fund Advisors
Dimensional Fund Advisors Austin, Texas $481B AUM 30.42% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Adage Capital Partners
Adage Capital Partners Boston, Massachusetts $64.8B AUM 42.7% 1-Year Est. Return
Man Group
Man Group London, United Kingdom $55.1B AUM 24.23% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

ALPS Advisors's FPRX Position: Q2 2019 in Review

ALPS Advisors sold out of Five Prime Therapeutics, Inc. (FPRX) in Q2 2019, closing a stake of 85,663 shares — an estimated $1.15M sold.

ALPS Advisors first reported a position in FPRX in Q1 2016 and held it in 13 quarters. The position peaked at $2.35M in Q3 2016. 114 funds tracked by Wall St. Rank hold FPRX as of Q2 2019.

  • ALPS Advisors reported no remaining Five Prime Therapeutics, Inc. position as of Q2 2019 after selling out during the quarter.
  • ALPS Advisors sold 85,663 Five Prime Therapeutics, Inc. shares in Q2 2019, an estimated $1.15M.
  • ALPS Advisors first reported a position in Five Prime Therapeutics, Inc. in Q1 2016 and held it in 13 quarters.
  • ALPS Advisors's Five Prime Therapeutics, Inc. position peaked at $2.35M in Q3 2016.
  • 114 funds tracked by Wall St. Rank held Five Prime Therapeutics, Inc. as of Q2 2019.

Based on ALPS Advisors's 13F filing for Q2 2019, filed 7 Aug 2019.